When I think of pharmaceutical company AstraZeneca (LSE: AZN) (NYSE: AZN.US), two factors jump out at me as the firm's greatest strengths and top the list of what makes the company attractive as an investment proposition.
(RTTNews.com) - The U.K.'sSunday Times reported this weekend that Pfizer ( PFE ) has proposed a $101 billion takeover of AstraZeneca PLC ( AZN ). AstraZeneca gapped open sharply higher Monday morning and is now up 3.62 at $67.11. The stock has ...
With reports that talks between AstraZeneca plc (ADR) (NYSE:AZN) and Pfizer are currently inactive, it remains to be seen who among the mentioned major drug companies will make a successful bid for AstraZeneca.
Dallas, Texas 04/22/2014 (ustradevoice) - AstraZeneca plc (ADR) (NYSE:AZN) rejected the huge deal of $101 billion that was offered by Pfizer Inc. (NYSE:PFE) as an attempt to takeover the British Drug Company.
While in biotech sector, AstraZeneca PLC (NYSE:AZN), Britain's second-biggest drug maker, has employed a pair of Wall Street investment banks to counsel it on any fresh acquisition move by its bigger U.S.